Background: The impact of systemic anticancer treatments on SARS-CoV-2-related mortality is still debatable.
Methods: By a retrospective analysis of patients with non-small-cell lung cancer (NSCLC) treated with first-line Pembrolizumab or in combination with chemotherapy (ChT) during the first surge of the pandemic.
Results: The adjusted risk of death was higher in patients treated with ChT + Pembrolizumab (HR 4.6, 1.2-17.4, p = 0.02). The SARS-CoV-2-related mortality rate was higher in patients treated with ChT + Pembrolizumab ( p = 0.03), ≥70 years ( p = 0.03) and current smokers ( p = 0.17).
Conclusions: The addition of ChT to immunotherapy could be associated with increased risk of mortality and higher SARS-CoV-2-related mortality rate.
【저자키워드】 SARS-CoV-2, Mortality, Immunotherapy, lung cancer, neutrophil-to-lymphocyte ratio (NLR).,